Accelerate Your Fibrosis Research

The distinction between prophylactic and therapeutic dosing in preclinical fibrosis models can determine clinical trial success. We discuss the appropriate dosing timelines across Bleomycin (IPF), GAN diet (MASH), and UUO (renal fibrosis) models, and the lessons from clinical failures of Simtuzumab and Selonsertib.

The Bleomycin pulmonary fibrosis model is the gold standard for IPF drug discovery. We explain solutions to its biggest challenges—"spontaneous resolution" and "variability"—using Micro-Sprayer technology for uniform administration and optimal study design.

There is no 'perfect MASH model.' We explain the importance of the 'Multi-Model Portfolio Strategy'—combining metabolic-focused (GAN) and fibrosis-focused (CDAHFD/CCl4) models—as seen in the development of Semaglutide.